Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $19.3600 (0.78%) ($18.8650 - $19.3600) on Thu. Dec. 30, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.12% (three month average) | RSI | 65 | Latest Price | $19.3600(0.78%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 1.2% a day on average for past five trading days. | Weekly Trend | TGTX advances 8.3% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(75%) ARKG(69%) IBB(67%) ARKK(64%) IWO(62%) | Factors Impacting TGTX price | TGTX will decline at least -3.06% in a week (0% probabilities). VIXM(-47%) VXX(-39%) UUP(-26%) UNG(-8%) USO(-5%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.06% (StdDev 6.12%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $19.13(1.2%) | 10 Day Moving Average | $18.36(5.45%) | 20 Day Moving Average | $17.51(10.57%) | To recent high | -45.6% | To recent low | 27.5% | Market Cap | $2.452b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |